Search

Your search keyword '"Wassie, Emnet A."' showing total 25 results
Start Over Author "Wassie, Emnet A."
25 results on '"Wassie, Emnet A."'

2. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Author

Tefferi, Ayalew, Guglielmelli, Paola, Larson, Dirk R., Finke, Christy, Wassie, Emnet A., Pieri, Lisa, Gangat, Naseema, Fjerza, Rajmonda, Belachew, Alem A., Lasho, Terra L., Ketterling, Rhett P., Hanson, Curtis A., Rambaldi, Alessandro, Finazzi, Guido, Thiele, Juergen, Barbui, Tiziano, Pardanani, Animesh, and Vannucchi, Alessandro M.

Published
2014
Full Text
View/download PDF

15. Chronic Myelomonocytic Leukemia in Young Patients: Molecular and Cytogenetic Predictors of Survival and Treatment Outcome

Author

Patnaik, Mrinal M., primary, Wassie, Emnet A, additional, Padron, Eric, additional, Onida, Francesco, additional, Itzykson, Raphael, additional, Lasho, Terra L, additional, Kosmider, Olivier, additional, Finke, Christy, additional, Hanson, Curtis A., additional, Ketterling, Rhett, additional, Komrokji, Rami S, additional, Tefferi, Ayalew, additional, and Solary, Eric, additional

Published
2014
Full Text
View/download PDF

20. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history

Author

Gangat, Naseema, primary, Wassie, Emnet A., additional, Lasho, Terra L., additional, Finke, Christy, additional, Ketterling, Rhett P., additional, Hanson, Curtis A., additional, Pardanani, Animesh, additional, Wolanskyj, Alexandra P., additional, Maffioli, Margherita, additional, Casalone, Rosario, additional, Passamonti, Francesco, additional, and Tefferi, Ayalew, additional

Published
2014
Full Text
View/download PDF

23. ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis.

Author

Pardanani, Animesh D., Lasho, Terra L., Finke, Christy, Zblewski, Darci L., Abdelrahman, Ramy A., Wassie, Emnet A., Gangat, Naseema, Hanson, Curtis A., Ketterling, Rhett P., and Tefferi, Ayalew

Subjects
GENETIC mutation, MAST cell disease, MYELOID leukemia genetics, LEUKEMIA, GENETICS
Abstract

The article discusses findings of a study on inferior survival in advanced systemic mastocytosis associated with mutation of ASXL1 and CBL genes. It states that KIT D816V mutation is considered as the driver mutation in systemic mastocytosis (SM), and mentions that patients with conditions like chronic myelomonocytic leukaemia (CMML), and acute myeloid leukaemia (AML) were analyzed. It notes that mutations in the non-KIT genes ASXL1, CBL and SETBP1 were associated with overall survival.

Published
2016
Full Text
View/download PDF

24. ASXL1and CBLMutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis

Author

Pardanani, Animesh, Lasho, Terra L., Finke, Christy, Zblewski, Darci, Abdelrahman, Ramy, Wassie, Emnet, Gangat, Naseema, Hanson, Curtis A., Ketterling, Rhett P., and Tefferi, Ayalew

Abstract

Background: KITD816V is considered the driver mutation in systemic mastocytosis (SM) however this mutation alone does not explain the diverse clinical manifestations of SM. While mutations in other myeloid-relevant genes have been reported in SM, their pattern(s) of co-segregation and prognostic value, independent of age and SM subtype, have not been fully defined in a mature dataset.

Published
2015
Full Text
View/download PDF

25. U2AF1mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia

Author

Tefferi, Ayalew, Finke, Christy, Lasho, Terra L, Wassie, Emnet A, Knudson, Ryan A, Ketterling, Rhett P, Hanson, Curtis A, and Pardanani, Animesh

Abstract

Spliceosome pathway gene mutations are recurrent in myeloid malignancies with the highest frequencies reported for myelodysplastic syndromes associated with ring sideroblasts (MDS-RS; 85%), MDS without RS (44%) and chronic myelomonocytic leukemia (CMML; 55%) (Nature 2011;478:64). SF3B1mutations were the most frequent (75%) in MDS-RS and SRSF2mutations in CMML (28%); U2AF1mutational frequencies were 12% in MDS without RS and 8% in CMML. We have previously described SRSF2(Blood. 2012;120:4168) and SF3B1(Leukemia. 2012;26:1135) mutations in 17% and 6.5% of patients with primary myelofibrosis (PMF); prognostic relevance was shown for the former but not the latter.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results